Evidence map›Paper›PMID 37752588›Full record

ArticleJournal of orthopaedic surgery and research2023

Long non-coding HOXA-AS3 contributes to osteosarcoma progression through the miR-1286/TEAD1 axis.

Xiangjun Xiao, Mingjiang Liu, Songlin Xie, Changxiong Liu, Xinfeng Huang, Xiongjie Huang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of orthopaedic surgery and research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Osteosarcoma in a ceRNET perspective.Journal of biomedical science · 2024
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xiangjun XiaoDepartment of Hand and Foot Surgery, Nanhua Hospital Affiliated to Nanhua University, Hengyang, 421002, China.
Mingjiang LiuDepartment of Orthopedic Trauma and Hand Surgery, Changsha Central Hospital Affiliated to Nanhua University, NO. 161 Shaoshan Nan Road, Changsha, 410018, China. liumingjiang2022@163.com.
Songlin XieDepartment of Hand and Foot Surgery, Nanhua Hospital Affiliated to Nanhua University, Hengyang, 421002, China.
Changxiong LiuDepartment of Hand and Foot Surgery, Nanhua Hospital Affiliated to Nanhua University, Hengyang, 421002, China.
Xinfeng HuangDepartment of Hand and Foot Surgery, Nanhua Hospital Affiliated to Nanhua University, Hengyang, 421002, China.
Xiongjie HuangDepartment of Hand and Foot Surgery, Nanhua Hospital Affiliated to Nanhua University, Hengyang, 421002, China.
University of South China · CNChangsha Central Hospital · CN

Funding

Major Special Project of Hunan Provincial Health and Family Planning Commission A2017018Major Special Project of Hunan Provincial Health and Family Planning Commission A20201906
6 · The paper itself

Abstract

Long non-coding RNA (lncRNA) HOXA cluster antisense RNA 3 (HOXA-AS3) regulates the progression of several types of human malignancy. However, the role and potential mechanism of HOXA-AS3 in osteosarcoma (OS) remain unknown. In this study, upregulation of HOXA-AS3 was observed in OS tissues and cell lines and associated with poor clinical outcomes. Silencing of HOXA-AS3 significantly inhibited the proliferation, migration and invasion of OS cells in vitro and suppressed the tumorigenesis of OS cells in vivo. Furthermore, knockdown of HOXA-AS3 inhibited the proliferation and migration of human umbilical vein endothelial cells (HUVECs) and epithelial-to-mesenchymal transition (EMT) in OS. Further investigation of this mechanism revealed that HOXA-AS3 could directly upregulate the expression of TEAD1 via its competing endogenous RNA (ceRNA) activity on miR-1286. This study clarified the oncogenic roles of the HOXA-AS3/miR-1286/TEAD1 axis in OS progression, suggesting a novel therapeutic target for OS.

Indexed as

Bone NeoplasmsMicroRNAsOsteosarcomaRNA, Long NoncodingCell Line, TumorCell ProliferationEndothelial CellsGene Expression Regulation, NeoplasticHumansTEA Domain Transcription FactorsMicroRNAsMIRN1286 microRNA, humanRNA, Long NoncodingTEAD1 protein, humanTEA Domain Transcription FactorsHOXA cluster antisense RNA 3MiR-1286OsteosarcomaTEA domain family mem

Identifiers

PMID37752588
PMCPMC10523635
OpenAlexW4387078106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.